Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Bladder Cancer

Free Subscription Articles published in PLoS One Retrieve available abstracts of 65 articles: HTML format

Single Articles

January 2024
1. KVIKSTAD V, Lillesand M, Gudlaugsson E, Mangrud OM, et al
   Proliferation and immunohistochemistry for p53, CD25 and CK20 in predicting prognosis of non-muscle invasive papillary urothelial carcinomas.
   PLoS One. 2024;19:e0297141.
   PubMed     Abstract available
   
   
   
2. CHEN LC, Yang HJ, Yu BH, Lee MS, et al
   Association of spironolactone use with risk of urinary tract cancer in the general population: A matched population-based cohort study.
   PLoS One. 2024;19:e0300391.
   PubMed     Abstract available
   
   
   
3. 
   Retraction: SATB1 Overexpression Regulates the Development and Progression in Bladder Cancer through EMT.
   PLoS One. 2024;19:e0301572.
   PubMed    
   
   
   January 2023
4. DIAS HF, Mochizuki Y, Kuhtreiber WM, Takahashi H, et al
   Bacille Calmette Guerin (BCG) and prevention of types 1 and 2 diabetes: Results of two observational studies.
   PLoS One. 2023;18:e0276423.
   PubMed     Abstract available
   
   
   
5. FUJITA N, Hatakeyama S, Okita K, Momota M, et al
   Impact of an optimized surveillance protocol based on the European Association of Urology substratification on surveillance costs in patients with primary high-risk non-muscle-invasive bladder cancer.
   PLoS One. 2023;18:e0275921.
   PubMed     Abstract available
   
   
   
6. AHRENFELDT J, Christensen DS, Ostergaard AB, Kisistok J, et al
   The ratio of adaptive to innate immune cells differs between genders and associates with improved prognosis and response to immunotherapy.
   PLoS One. 2023;18:e0281375.
   PubMed     Abstract available
   
   
   
7. LIEDBERG F, Hagberg O, Haggstrom C, Aljabery F, et al
   Preoperative upper tract invasive diagnostic modalities are associated with intravesical recurrence following surgery for upper tract urothelial carcinoma: A population-based study.
   PLoS One. 2023;18:e0281304.
   PubMed     Abstract available
   
   
   
8. WEINBERG L, Aitken SAA, Kaldas P, Fletcher L, et al
   Postoperative complications and hospital costs following open radical cystectomy: A retrospective study.
   PLoS One. 2023;18:e0282324.
   PubMed     Abstract available
   
   
   
9. LIU CL, Tsai HW, Peng SL, Chang CP, et al
   CDCP1 (CUB domain containing protein 1) is a potential urine-based biomarker in the diagnosis of low-grade urothelial carcinoma.
   PLoS One. 2023;18:e0281873.
   PubMed     Abstract available
   
   
   
10. SMITH-TOGOBO C, Mprah R, Yeboah EA, Anyidoho HK, et al
    Detection of cytological abnormalities in urothelial cells from individuals previously exposed or currently infected with Schistosoma haematobium.
    PLoS One. 2023;18:e0278202.
    PubMed     Abstract available
    
    
    
11. 
    Expression of Concern: The prognostic significance of long noncoding RNAs in bladder cancer: A meta-analysis.
    PLoS One. 2023;18:e0284938.
    PubMed    
    
    
    
12. HAMID ARAH, Syadza YZ, Yausep OE, Christanto RBI, et al
    The expression of stem cells markers and its effects on the propensity for recurrence and metastasis in bladder cancer: A systematic review.
    PLoS One. 2023;18:e0269214.
    PubMed     Abstract available
    
    
    
13. VAINER G, Huang L, Emancipator K, Nuti S, et al
    Equivalence of laboratory-developed test and PD-L1 IHC 22C3 pharmDx across all combined positive score indications.
    PLoS One. 2023;18:e0285764.
    PubMed     Abstract available
    
    
    
14. SATO N, Mori KP, Sakai K, Miyata H, et al
    Exploring the mechanism of BK polyomavirus-associated nephropathy through consensus gene network approach.
    PLoS One. 2023;18:e0282534.
    PubMed     Abstract available
    
    
    
15. YUAN Q, Hu J, Yuan F, An J, et al
    Predictive role of pretreatment skeletal muscle mass index for long-term survival of bladder cancer patients: A meta-analysis.
    PLoS One. 2023;18:e0288077.
    PubMed     Abstract available
    
    
    
16. LEE J, Kim E, Park J, Choi S, et al
    Pre-analytical handling conditions and protein marker recovery from urine extracellular vesicles for bladder cancer diagnosis.
    PLoS One. 2023;18:e0291198.
    PubMed     Abstract available
    
    
    
17. LEONARDO K, Mirza H, Seno DH, Purnomo N, et al
    Transperitoneal vs extraperitoneal radical cystectomy: A systematic review and meta-analysis.
    PLoS One. 2023;18:e0294809.
    PubMed     Abstract available
    
    
    
18. WANG E, Hagberg O, Malmstrom PU
    The association between BCG treatment in patients with bladder cancer and subsequent risk of developing Alzheimer and other dementia.-A Swedish nationwide cohort study from 1997 to 2019.
    PLoS One. 2023;18:e0292174.
    PubMed     Abstract available
    
    
    January 2022
19. SANGSTER AG, Gooding RJ, Garven A, Ghaedi H, et al
    Mutually exclusive mutation profiles define functionally related genes in muscle invasive bladder cancer.
    PLoS One. 2022;17:e0259992.
    PubMed     Abstract available
    
    
    
20. HEMMINKI K, Forsti A, Hemminki A, Ljungberg B, et al
    Survival in bladder and upper urinary tract cancers in Finland and Sweden through 50 years.
    PLoS One. 2022;17:e0261124.
    PubMed     Abstract available
    
    
    
21. FU Y, Sun S, Bi J, Kong C, et al
    An HDAC9-associated immune-related signature predicts bladder cancer prognosis.
    PLoS One. 2022;17:e0264527.
    PubMed     Abstract available
    
    
    
22. ISONO M, Okubo K, Asano T, Sato A, et al
    Ataxia telangiectasia and Rad3-related inhibition by AZD6738 enhances gemcitabine-induced cytotoxic effects in bladder cancer cells.
    PLoS One. 2022;17:e0266476.
    PubMed     Abstract available
    
    
    
23. KANG DH, Cho KS, Moon YJ, Chung DY, et al
    Effect of neoadjuvant chemotherapy on overall survival of patients with T2-4aN0M0 bladder cancer: A systematic review and meta-analysis according to EAU COVID-19 recommendation.
    PLoS One. 2022;17:e0267410.
    PubMed     Abstract available
    
    
    
24. AGHAMIR SMK, Khatami F, Farrokhpour H, Oliveira Reis L, et al
    Oncologic outcomes of Bacillus Calmette-Guerin therapy in elderly patients with non-muscle-invasive bladder cancer: A meta-analysis.
    PLoS One. 2022;17:e0267934.
    PubMed     Abstract available
    
    
    
25. OKORIE CL, Gatsby E, Schroeck FR, Ould Ismail AA, et al
    Using electronic health records to streamline provider recruitment for implementation science studies.
    PLoS One. 2022;17:e0267915.
    PubMed     Abstract available
    
    
    
26. 
    Retraction: MicroRNA-137 Upregulation Increases Bladder Cancer Cell Proliferation and Invasion by Targeting PAQR3.
    PLoS One. 2022;17:e0269903.
    PubMed    
    
    
    
27. ABDELGAWAD A, Hashem A, Mosbah A, Eissa LA, et al
    A prospective trial investigating the role of Serum 25-Hydroxyvitamin D in diagnosis and prognosis of bladder cancer.
    PLoS One. 2022;17:e0266371.
    PubMed     Abstract available
    
    
    
28. GULYAS D, Kovacs G, Jankovics I, Meszaros L, et al
    Effects of the combination of a monoclonal agonistic mouse anti-OX40 antibody and toll-like receptor agonists: Unmethylated CpG and LPS on an MB49 bladder cancer cell line in a mouse model.
    PLoS One. 2022;17:e0270802.
    PubMed     Abstract available
    
    
    
29. GLEICHENHAGEN J, Arndt C, Casjens S, Topfer C, et al
    Exploring solid-phase proximity ligation assay for survivin detection in urine.
    PLoS One. 2022;17:e0270535.
    PubMed     Abstract available
    
    
    
30. JURI H, Higashiyama A, Yamamoto K, Narumi Y, et al
    Comparison of reduced field-of-view DWI and full field-of view DWI for the differentiation between non-muscle invasive bladder cancer and muscle invasive bladder cancer using VI-RADS.
    PLoS One. 2022;17:e0271470.
    PubMed     Abstract available
    
    
    
31. DE WISPELAERE N, Rico SD, Bauer M, Luebke AM, et al
    High prevalence of p16 staining in malignant tumors.
    PLoS One. 2022;17:e0262877.
    PubMed     Abstract available
    
    
    
32. LUND HAHEIM L, Thelle DS, Ronningen KS, Olsen I, et al
    Low level of antibodies to the oral bacterium Tannerella forsythia predicts bladder cancers and Treponema denticola predicts colon and bladder cancers: A prospective cohort study.
    PLoS One. 2022;17:e0272148.
    PubMed     Abstract available
    
    
    
33. GILLEZEAU C, Movva N, van Gerwen M, Rabon-Stith K, et al
    Interferon gamma expression and mortality in unselected cohorts of urothelial bladder cancer patients.
    PLoS One. 2022;17:e0271339.
    PubMed     Abstract available
    
    
    
34. MOON YJ, Cho KS, Jeong JY, Chung DY, et al
    Effects of intravesical BCG maintenance therapy duration on recurrence rate in high-risk non-muscle invasive bladder cancer (NMIBC): Systematic review and network meta-analysis according to EAU COVID-19 recommendations.
    PLoS One. 2022;17:e0273733.
    PubMed     Abstract available
    
    
    
35. HOLMBERG L, Hagberg O, Haggstrom C, Gardmark T, et al
    Number of transurethral procedures after non-muscle-invasive bladder cancer and survival in causes other than bladder cancer.
    PLoS One. 2022;17:e0274859.
    PubMed     Abstract available
    
    
    
36. MACHLEID F, Ho-Wrigley J, Chowdhury A, Paliah A, et al
    Cost-utility analysis of robotic-assisted radical cystectomy for bladder cancer compared to open radical cystectomy in the United Kingdom.
    PLoS One. 2022;17:e0270368.
    PubMed     Abstract available
    
    
    
37. AZUMA T, Kano M, Iwata S, Honda S, et al
    Utility of periodic medical questionnaires and examinations for immune-related adverse event screening: A prospective observational study.
    PLoS One. 2022;17:e0274451.
    PubMed     Abstract available
    
    
    
38. ZHOU W, Liu J, Mao D, Hu C, et al
    The clinical efficacy and safety of equipment-assisted intravesical instillation of mitomycin C after transurethral resection of bladder tumour in patients with nonmuscular invasive bladder cancer: A meta-analysis.
    PLoS One. 2022;17:e0276453.
    PubMed     Abstract available
    
    
    
39. KARIMI A, Shobeiri P, Azadnajafabad S, Masinaei M, et al
    A global, regional, and national survey on burden and Quality of Care Index (QCI) of bladder cancer: The global burden of disease study 1990-2019.
    PLoS One. 2022;17:e0275574.
    PubMed     Abstract available
    
    
    
40. ZHAO H, Tse RT, Cheng CK, Wong CY, et al
    In vitro cytotoxicity of human urine and its potential toxic parameters towards bladder cancer cells.
    PLoS One. 2022;17:e0276127.
    PubMed     Abstract available
    
    
    
41. KIKUCHI H, Osawa T, Abe T, Matsumoto R, et al
    Quality improvement in managing patients with non-muscle-invasive bladder cancer by introducing a surgical checklist for transurethral resection of bladder tumor.
    PLoS One. 2022;17:e0276816.
    PubMed     Abstract available
    
    
    
42. HSIEH HC, Wang CL, Chen CS, Yang CK, et al
    The prognostic impact of lymph node dissection for clinically node-negative upper urinary tract urothelial carcinoma in patients who are treated with radical nephroureterectomy.
    PLoS One. 2022;17:e0278038.
    PubMed     Abstract available
    
    
    January 2021
43. LAYTRAGOON LEWIN N, Karlsson JE, Robinsson D, Fagerberg M, et al
    Influence of single nucleotide polymorphisms among cigarette smoking and non-smoking patients with coronary artery disease, urinary bladder cancer and lung cancer.
    PLoS One. 2021;16:e0243084.
    PubMed     Abstract available
    
    
    
44. BESSA A, Rammant E, Enting D, Bryan RT, et al
    The need for supportive mental wellbeing interventions in bladder cancer patients: A systematic review of the literature.
    PLoS One. 2021;16:e0243136.
    PubMed     Abstract available
    
    
    
45. LIEDBERG F, Hagberg O, Aljabery F, Gardmark T, et al
    Cumulative incidence of midline incisional hernia and its surgical treatment after radical cystectomy and urinary diversion for bladder cancer: A nation-wide population-based study.
    PLoS One. 2021;16:e0246703.
    PubMed     Abstract available
    
    
    
46. HUANG CY, Wang SC, Chan L, Hsieh TY, et al
    Gender differences in trends of bladder cancer mortality-to-incidence ratios according to health expenditure in 55 countries.
    PLoS One. 2021;16:e0244510.
    PubMed     Abstract available
    
    
    
47. UYSAL D, Kowalewski KF, Kriegmair MC, Wirtz R, et al
    A comprehensive molecular characterization of the 8q22.2 region reveals the prognostic relevance of OSR2 mRNA in muscle invasive bladder cancer.
    PLoS One. 2021;16:e0248342.
    PubMed     Abstract available
    
    
    
48. WANG K, Yang JC, Jang YJ, Chen GY, et al
    19-(Benzyloxy)-19-oxojolkinolide B (19-BJB), an ent-abietane diterpene diepoxide, inhibits the growth of bladder cancer T24 cells through DNA damage.
    PLoS One. 2021;16:e0248468.
    PubMed     Abstract available
    
    
    
49. JIANG H, Gu X, Zuo Z, Tian G, et al
    Prognostic value of circulating tumor cells in patients with bladder cancer: A meta-analysis.
    PLoS One. 2021;16:e0254433.
    PubMed     Abstract available
    
    
    
50. MUILWIJK T, Akand M, Daelemans S, Marien K, et al
    Stromal marker fibroblast activation protein drives outcome in T1 non-muscle invasive bladder cancer.
    PLoS One. 2021;16:e0257195.
    PubMed     Abstract available
    
    
    
51. KLOSE K, Packeiser EM, Muller P, Granados-Soler JL, et al
    Metformin and sodium dichloroacetate effects on proliferation, apoptosis, and metabolic activity tested alone and in combination in a canine prostate and a bladder cancer cell line.
    PLoS One. 2021;16:e0257403.
    PubMed     Abstract available
    
    
    
52. LEE YH, Lee MM, De Silva DM, Roy A, et al
    Autocrine signaling by receptor tyrosine kinases in urothelial carcinoma of the bladder.
    PLoS One. 2021;16:e0241766.
    PubMed     Abstract available
    
    
    
53. ZLOWOCKA-PERLOWSKA E, Debniak T, Slojewski M, van de Wetering T, et al
    Survival of bladder or renal cancer in patients with CHEK2 mutations.
    PLoS One. 2021;16:e0257132.
    PubMed     Abstract available
    
    
    
54. CHANG YH, Tam HL, Lu MC, Huang HS, et al
    Gemcitabine-induced Gli-dependent activation of hedgehog pathway resists to the treatment of urothelial carcinoma cells.
    PLoS One. 2021;16:e0254011.
    PubMed     Abstract available
    
    
    
55. KIM SH, Song MK, Ku JH, Kang SH, et al
    A retrospective multicenter comparison of conditional cancer-specific survival between laparoscopic and open radical nephroureterectomy in locally advanced upper tract urothelial carcinoma.
    PLoS One. 2021;16:e0255965.
    PubMed     Abstract available
    
    
    
56. INKOL JM, Hocker SE, Mutsaers AJ
    Combination therapy with cannabidiol and chemotherapeutics in canine urothelial carcinoma cells.
    PLoS One. 2021;16:e0255591.
    PubMed     Abstract available
    
    
    
57. HE X, Anthony DC, Catoni Z, Cao W, et al
    Pulmonary tumor embolism: A retrospective study over a 30-year period.
    PLoS One. 2021;16:e0255917.
    PubMed     Abstract available
    
    
    
58. ODA S, Fujisawa M, Chunning L, Ito T, et al
    Expression of Spred2 in the urothelial tumorigenesis of the urinary bladder.
    PLoS One. 2021;16:e0254289.
    PubMed     Abstract available
    
    
    
59. AL-EZZI EM, Veitch ZW, Salah SH, Van der Kwast TH, et al
    Genomic characterization of non-schistosomiasis-related squamous cell carcinoma of the urinary bladder: A retrospective exploratory study.
    PLoS One. 2021;16:e0259272.
    PubMed     Abstract available
    
    
    
60. LEMINSKI A, Kaczmarek K, Byrski T, Slojewski M, et al
    Neoadjuvant chemotherapy with dose dense MVAC is associated with improved survival after radical cystectomy compared to other cytotoxic regimens: A tertiary center experience.
    PLoS One. 2021;16:e0259526.
    PubMed     Abstract available
    
    
    January 2020
61. REED O, Jubber I, Griffin J, Noon AP, et al
    Occupational bladder cancer: A cross section survey of previous employments, tasks and exposures matched to cancer phenotypes.
    PLoS One. 2020;15:e0239338.
    PubMed     Abstract available
    
    
    
62. TELEKA S, Hindy G, Drake I, Poveda A, et al
    Blood pressure and bladder cancer risk in men by use of survival analysis and in interaction with NAT2 genotype, and by Mendelian randomization analysis.
    PLoS One. 2020;15:e0241711.
    PubMed     Abstract available
    
    
    
63. AZUMA T, Sato Y, Ohno T, Azuma M, et al
    Serum soluble B7-H3 is a prognostic marker for patients with non-muscle-invasive bladder cancer.
    PLoS One. 2020;15:e0243379.
    PubMed     Abstract available
    
    
    
64. 
    Retraction: MicroRNA-214 Suppresses Oncogenesis and Exerts Impact on Prognosis by Targeting PDRG1 in Bladder Cancer.
    PLoS One. 2020;15:e0244274.
    PubMed    
    
    
    
65. KARDOS J, Rose TL, Manocha U, Wobker SE, et al
    Development and validation of a NanoString BASE47 bladder cancer gene classifier.
    PLoS One. 2020;15:e0243935.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.